<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211129</url>
  </required_header>
  <id_info>
    <org_study_id>ZYS2019-02</org_study_id>
    <nct_id>NCT04211129</nct_id>
  </id_info>
  <brief_title>Effect of Acupuncture on Patients With Crohn's Disease in Remission</brief_title>
  <official_title>Effect of Acupuncture on Crohn's Disease Via the Regulation of Trp-kyn Metabolism in Brain-gut Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute of Acupuncture, Moxibustion and Meridian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Institute of Acupuncture, Moxibustion and Meridian</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the therapeutic effect of acupuncture on Crohn's disease in remission and its
      influence of brain functional activity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Effect of acupuncture on symptoms （functional gastrointestinal symptoms, Fatigue,
           insomnia, depression, anxiety and perceived stress）of CD

        2. Effect of acupuncture on brain functional activity of CD
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>Week 12</time_frame>
    <description>The mean change in GSRS from baseline. The higher the score, the worse the condition. Greater than 0, the upper limit is 45.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>Week 24,36,48,52</time_frame>
    <description>The mean change in GSRS from baseline. The higher the score, the worse the condition. Greater than 0, the upper limit is 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional fatigue inventory-20 (MFI-20)</measure>
    <time_frame>Week 12, 24,36,48,52</time_frame>
    <description>The mean change in MFI-20 from baseline. The higher the score, the worse the condition. The score range from 20 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh sleep quality index (PSQI)</measure>
    <time_frame>Week 12, 24,36,48,52</time_frame>
    <description>The mean change in PSQI from baseline. The higher the score, the worse the condition. The score range from 0 to 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The insomnia severity index (ISI)</measure>
    <time_frame>Week 12, 24,36,48,52</time_frame>
    <description>The mean change in ISI from baseline. The higher the score, the worse the condition. The score range from 0 to 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's disease activity index （CDAI）score</measure>
    <time_frame>Week 12, 24,36,48,52</time_frame>
    <description>The mean change in CDAI from baseline. The higher the score, the worse the condition. Greater than 0, no upper limit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory bowel disease questionnaire (IBDQ)</measure>
    <time_frame>Week 12 and 24.</time_frame>
    <description>The mean change in IBDQ from baseline. The higher the score, the worse the condition.The score is range from 32 to 224.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital anxiety and depression scale (HADS)</measure>
    <time_frame>Week 12 and 24</time_frame>
    <description>The mean change in HADS from baseline. The higher the score, the more serious the disease. The depression and anxiety score is range from 0 to 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of recurrences</measure>
    <time_frame>Week 52</time_frame>
    <description>Defined as CDAI &gt; 150 and increase ≥ 70 points or need to adjust drug to control disease condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain functional and structural changes</measure>
    <time_frame>Week 12</time_frame>
    <description>measured by functional MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>acupuncture group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving acupuncture and moxibustion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham acupuncture group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Receiving sham acupuncture and sham moxibustion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>acupuncture</intervention_name>
    <description>Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.</description>
    <arm_group_label>acupuncture group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham acupuncture</intervention_name>
    <description>Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.</description>
    <arm_group_label>sham acupuncture group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 16-70;

          2. patients in remission (CDAI &lt; 150);

          3. patients were not taking medication or were only taking one or more of the following
             drugs: [prednisone ≤15mg/d, azathioprine (≤1mg/kg/d), methotrexate (≤15mg/w) or
             mesalazine (≤4g/d)] and prednisone was used for at least 1 month, while azathioprine,
             methotrexate or mesalazine was used for at least 3 months;

          4. those who did not use TNF alpha and other preparations within 3 months before entering
             the study;

          5. those who have never experienced acupuncture;

          6. patients signing informed consent.

        Exclusion Criteria:

          1. patients who are recently pregnant or in pregnancy or lactation;

          2. patients with serious organic diseases;

          3. patients diagnosed as psychosis;

          4. patients who take antibiotics, probiotics, traditional Chinese medicine and other
             drugs at the same time, or who suffer from multiple diseases and need to take other
             drugs for a long time, and may affect the observation of the efficacy of this trial;

          5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye
             diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious
             extraintestinal manifestations;

          6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and
             obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and
             other complications;

          7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal
             surgery in the past half a year;

          8. there are skin diseases or defects in the selected area of acupuncture and moxibustion
             that cannot be performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huangan Wu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Research Institute of Acupuncture and Meridian</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunhui Bao, MD, PhD</last_name>
    <phone>+862164395973</phone>
    <email>baochunhui789@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Research Institute of Acupuncture and Meridian</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunhui Bao, MD, PhD</last_name>
      <phone>+862164395973</phone>
      <email>baochunhui789@126.com</email>
    </contact>
    <contact_backup>
      <last_name>MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Huangan Wu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yueyang Hospital of Integrated Traditional Chinese and Western medicine, Shanghai university of traditional Chinese medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200437</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guona Li, MD</last_name>
      <phone>+862165161782</phone>
      <email>liguonaaa@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 22, 2019</study_first_submitted>
  <study_first_submitted_qc>December 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 22, 2019</last_update_submitted>
  <last_update_submitted_qc>December 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acupuncture</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>brain functional activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

